Antifungal Susceptibility Testing: A Primer for Clinicians

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Clinicians treating patients with fungal infections may turn to susceptibility testing to obtain information regarding the activity of different antifungals against a specific fungus that has been cultured. These results may then be used to make decisions regarding a patient's therapy. However, for many fungal species that are capable of causing invasive infections, clinical breakpoints have not been established. Thus, interpretations of susceptible or resistant cannot be provided by clinical laboratories, and this is especially true for many molds capable of causing severe mycoses. The purpose of this review is to provide an overview of susceptibility testing for clinicians, including the methods used to perform these assays, their limitations, how clinical breakpoints are established, and how the results may be put into context in the absence of interpretive criteria. Examples of when susceptibility testing is not warranted are also provided.

Original languageEnglish (US)
Article numberofab444
JournalOpen Forum Infectious Diseases
Issue number11
StatePublished - Nov 1 2021


  • antifungal
  • clinical breakpoint
  • susceptibility testing

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology


Dive into the research topics of 'Antifungal Susceptibility Testing: A Primer for Clinicians'. Together they form a unique fingerprint.

Cite this